Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

National temporal trends and demographic disparities in nutritional anemia-relatedmortality in the United States, 1999–2024

Fatima Ali, Ibrahim Hassan, Amna Khalid et al. Nov 03, 2025 pp. 7982-7982 10.1182/blood-2025-7982

Abstract Background: Nutritional anemias remain a preventable cause of morbidity and mortality in the United States, dis...

Contrasting real-world treatment landscapes of bispecific antibodies and CAR-T cells in multiple myeloma and diffuse large B-cell lymphoma

Chrystal Ferguson, Rebecca Simons, Serafina Adabra et al. Nov 03, 2025 pp. 8153-8153 10.1182/blood-2025-8153

Abstract Introduction: Bispecific antibodies and Chimeric Antigen Receptor (CAR)-T cell therapies are transformative treatments for Multiple...

Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells

Kerttu Kalander, Katri Oksa, Selma Sorri et al. Nov 03, 2025 pp. 5891-5891 10.1182/blood-2025-5891

Abstract Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of patients with relapsed and refractory (R/R) d...

Single-center experience with mitoxantrone hydrochloride liposome-based therapy for patients with myeloid sarcoma

Wenjuan He, Qiuling Wu, Li Weiming et al. Nov 03, 2025 pp. 3406-3406 10.1182/blood-2025-3406

Abstract Background: Myeloid sarcoma (MS) accounts for 3% to 8% of acute myeloid leukemia (AML) cases and is characterized by an extramedulla...

Validation of the artificial intelligence prediction of acute leukemia tool in a Latin American retrospective cohort

Jade Zezzi Martins do Nascimento, Aline Nishimoto, Amanda Inácio Dias Ennes et al. Nov 03, 2025 pp. 4362-4362 10.1182/blood-2025-4362

Abstract Introduction: Early and accurate identification of acute leukemia (AL) subtypes—acute lymphoblastic leukemia (ALL), acute myeloid l...

Ivosidenib with or without hypomethylating agent in IDH1-mutated AML: Real-world evidence to inform frontline therapy

Tarun Bhagnani, Pierantonio Russo, Ramaa Nathan et al. Nov 03, 2025 pp. 6963-6963 10.1182/blood-2025-6963

Abstract Introduction IDH1-mutated (mIDH1) acute myeloid leukemia (AML) is defined by D-2 hydroxyglutarate-driven epigenetic disruption and...

Comparative analysis between inhibitor screen and mini bethesda assay to diagnose low titre inhibitors in hemophilia patients - an experience from a hemophilia comprehensive care center in India

Madhura Deshpande, Kannan Subramanian, Rajesh Phatale et al. Nov 03, 2025 pp. 1296-1296 10.1182/blood-2025-1296

Abstract Introduction : The most common treatment-associated complication in patients with Hemophilia A is the development of inhibitors. In...

Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant

Ryan Woodall, Alexander Pozhitkov, Azra Borogovac et al. Nov 03, 2025 pp. 7451-7451 10.1182/blood-2025-7451

Abstract Introduction: Daratumumab, a CD38-targeted monoclonal antibody, is a highly effective therapy in multiple myeloma. Beyond its anti-...

The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma

Prashant Kapoor, Morie Gertz, Paul Dizona et al. Nov 03, 2025 pp. 2281-2281 10.1182/blood-2025-2281

Abstract Background Multiple myeloma, the second most common hematologic malignancy, has witnessed incremental progress in its management ov...

A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)

Naseema Gangat, Ayalew Tefferi, Aaron Gerds et al. Nov 03, 2025 pp. 2053-2053 10.1182/blood-2025-2053

Abstract Background and Significance: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with pathologic...

Phase I trial of ruxolitinib plus fostamatinib for the treatment of steroid refractory chronic graft versus host disease

Chenyu Lin, Zhiguo Li, Kouros Owzar et al. Nov 03, 2025 pp. 2479-2479 10.1182/blood-2025-2479

Abstract Background and Significance: Current therapies for steroid-refractory chronic graft versus host disease (SR-cGVHD) feature limited...

Code red (Código Rojo): Multimodal generative AI for specialized hematology education

Carlos Pérez Míguez, Michael Calviño Suárez, Davide Crucitti et al. Nov 03, 2025 pp. 4331-4331 10.1182/blood-2025-4331

Abstract Introduction Recent advances in artificial intelligence—particularly in Natural Language Processing via Large Language Models (LLMs...

Trends and disparities in anemia and pneumonia-related mortality in the United States from 1999 to 2023: A CDC wonder database analysis

Dania Hussain, Muhammad Ali, Alina Fatima et al. Nov 03, 2025 pp. 8003-8003 10.1182/blood-2025-8003

Abstract Introduction: Anemia and pneumonia are prevalent and often coexisting conditions that contribute significantly to morbidity and mor...

Negative feedback regulation of nfkb, MAPK, and JAK-STAT drives adaptive resistance to gilteritinib in AML

Meenu Kesarwani, Mohammad Azhar, Zachary Kincaid et al. Nov 03, 2025 pp. 1514-1514 10.1182/blood-2025-1514

Abstract Kinase activating mutations in the FMS like tyrosine kinase 3 (FLT3) gene represent the most frequent molecular lesion in acute mye...

Efficacy and safety of a retreatment with inotuzumab ozogamicin in adult patients with relapsed/refractory acute lymphoblastic leukemia: A Campus ALL study

Gianluca Cavallaro, Ferdinando Porretto, Patrizia Chiusolo et al. Nov 03, 2025 pp. 5127-5127 10.1182/blood-2025-5127

Abstract Introduction Inotuzumab ozogamicin (Ino) is an anti-CD22 immuno-conjugated monoclonal antibody, which has impro...

Circadian rhythm disruption impairs CAR-T cell efficacy by promoting an immunosuppressive tumor microenvironment through enhancing monocyte-MDSC infiltration

Wanying Zhang, Zhaozhao Chen, Liman Su et al. Nov 03, 2025 pp. 2333-2333 10.1182/blood-2025-2333

Abstract Background: Circadian rhythm disruption is associated with various chronic diseases and cancers, and may influence cancer immunothe...

Reprogramming CAR-NK cells with IL-7/IL-7Rα to amplify STAT1 signaling and activate bystander T cells for enhanced immunotherapy

Andreia Maia, Mubin Tarannum, Sara Piccinelli et al. Nov 03, 2025 pp. 4129-4129 10.1182/blood-2025-4129

Abstract Chimeric antigen receptor (CAR)-T and CAR-NK cell therapies have shown promise in cancer treatment, but their effectiveness remains...

Pharmacologic activators of immunoproteasomes unmask actionable public and private neoantigens in multiple myeloma patients

James Driscoll, James Ignatz-Hoover, John D'Cruz et al. Nov 03, 2025 pp. 3954-3954 10.1182/blood-2025-3954

Abstract Immunotherapy has emerged as a powerful tool for myeloma-directed cytotoxicity with the unique potential to induce immune memory an...

Multiparametric integration improves diagnostic categorisation of mature, non-CLL B-cell leukemias including atypical CLL - results from the prospective enable-NGS study

Li Yuan Chan, Matthew Cross, Grzegorz Pietka et al. Nov 03, 2025 pp. 1753-1753 10.1182/blood-2025-1753

Abstract Introduction Enhanced diagnostic categorisation improves patient access to information, novel therapies and clinical trials. We pre...

Lactylation-related LGALS1 promotes immunosuppressive tumor microenvironment and venetoclax resistance in Acute Myeloid Leukemia

Bobin Su, Yan Zhang, Changqing Jiao et al. Nov 03, 2025 pp. 5009-5009 10.1182/blood-2025-5009

Abstract Acute myeloid leukemia (AML) is a highly heterogeneous and immunosuppressive hematologic malignancy. Novel therapies like venetocla...

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

Jessica Li, Yang Shi, Linlin Xu et al. Nov 03, 2025 pp. 5681-5681 10.1182/blood-2025-5681

Abstract Background: The CLL-International Prognostic Index (IPI) is a weighted scoring system that combines 5 factors (age, clinical stage,...

Adrenal insufficiency in sickle cell disease: A  Case series of a potentially underrecognized complication

Rebecca Zhuang, Lauren Bolster Nov 03, 2025 pp. 6526-6526 10.1182/blood-2025-6526

Abstract Introduction: Endocrinopathies, including adrenal insufficiency (AI), are recognized complications that can occur in sickle cell di...

Treatment patterns and outcomes among warm autoimmune hemolytic anemia patients receiving rituximab in the United States: A retrospective database study

Louis Jackson, Shannon Ferrante, Jacqueline Pesa et al. Nov 03, 2025 pp. 4459-4459 10.1182/blood-2025-4459

Abstract Background: Rituximab (RTX) is one of the preferred initial treatment options for patients living with warm autoimmune hemolytic an...

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Raajit Rampal, John Mascarenhas, Sebastian Grosicki et al. Nov 03, 2025 pp. 910-910 10.1182/blood-2025-910

Abstract Janus kinase inhibitor (JAKi) monotherapy, the standard of care for myelofibrosis (MF), improves splenomegaly and symptom burden bu...

NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma

Robert Chavez, Jonathan Patton, James Ackley et al. Nov 03, 2025 pp. 3956-3956 10.1182/blood-2025-3956

Abstract Introduction: The t(4;14) translocation is present in ~12% of Multiple Myeloma (MM) patients and uniformly results in high levels of...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page